Navigation Links
Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Date:11/13/2011

PRINCETON, N.J., Nov. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Lazard Capital Markets 8th Annual Healthcare Conference to be held November 15 to 16, 2011 at the Pierre Hotel, New York. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Tuesday, November 15 at 3:00 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcasts will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently being studied in an interferon-free, Phase 3 program (FISSION and POSITRON) and in five Phase 2b trials in subjects with all HCV genotypes. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, is in QUANTUM, a Phase 2b interferon-free trial of PSI-7977 and PSI-938 in subjects with all HCV genotypes. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 865-0693 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Webcast an Investor Event from the AASLD Meeting
2. Pharmasset to Present at Four Upcoming Investor Conferences
3. Pharmasset to Present at Canaccord Adams Conference
4. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
7. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
8. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
11. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... will hold an open house for regional manufacturers at its Maple Grove, Minnesota ... Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers of ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... ... April 27, 2016 , ... A compact PET ... Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and ... in small animal subjects. Simultaneous PET/MRI imaging offers a solution to many challenges ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Christie LLP as an associate in the firm’s Intellectual Property practice group. , ... and electromechanical patent applications. He has an electrical engineering and computer engineering background, ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):